Our purpose is to accelerate the development of cancer medicines and treatments
Rewriting Cancer
We are delighted to announce our involvement in Rewriting Cancer, a series produced for UICC by BBC StoryWorks Commercial Productions. This unique project examines the complexity of cancer and the changes in treatments that are required to achieve better outcomes for patients. Watch and learn how we and the other participants are Rewriting Cancer. In oncology we all share a common goal to improve the lives of patients.
Talk to our team
We’d like to hear from you
Read the latest news from Ellipses Pharma
EP0062 TIP ASCO 2026 Poster
EP0062 TIP ASCO 2026 Poster {{ vc_btn: title=Download+as+PDF&style=custom&custom_background=%23000066&custom_text=%23ffffff&shape=round&size=lg&align=center&css=.vc_custom_1786109564984%7Bpadding-top%3A+15px+%21important%3B%7D&link=url%3Ahttps%253A%252F%252Fellipses.life%252Fwp-content%252Fuploads%252F2026%252F08%252FASCO26_EP0062-TIP_poster.pdf%7Ctarget%3A_blank }} About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise the [...]
EP0089 ASCO 2026 Poster
EP0089 ASCO 2026 Poster {{ vc_btn: title=Download+as+PDF&style=custom&custom_background=%23000066&custom_text=%23ffffff&shape=round&size=lg&align=center&css=.vc_custom_1786102071864%7Bpadding-top%3A+15px+%21important%3B%7D&link=url%3Ahttps%253A%252F%252Fellipses.life%252Fwp-content%252Fuploads%252F2026%252F08%252FEP0089-101_ASCO-2026-TiP-Poster.pdf%7Ctarget%3A_blank }} About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise the time [...]
Pivotal trial data for EP0031 in RET +ve advanced NSCLC, to be presented at ASCO 2026
Pivotal trial data for EP0031 in RET +ve advanced NSCLC, to be presented at ASCO 2026 London, May 22, 2026 Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive [...]
